 Connection
Robert Keith to Carcinoma, Non-Small-Cell Lung
This is a "connection" page, showing publications Robert Keith has written about Carcinoma, Non-Small-Cell Lung.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.481 |
|
|
|
-
Moghaddam SJ, Savai R, Salehi-Rad R, Sengupta S, Kammer MN, Massion P, Beane JE, Ostrin EJ, Priolo C, Tennis MA, Stabile LP, Bauer AK, Sears CR, Szabo E, Rivera MP, Powell CA, Kadara H, Jenkins BJ, Dubinett SM, Houghton AM, Kim CF, Keith RL. Premalignant Progression in the Lung: Knowledge Gaps and Novel Opportunities for Interception of Non-Small Cell Lung Cancer. An Official American Thoracic Society Research Statement. Am J Respir Crit Care Med. 2024 09 01; 210(5):548-571.
Score: 0.451
-
Dwyer-Nield LD, McArthur DG, Hudish TM, Hudish LI, Mirita C, Sompel K, Smith AJ, Alavi K, Ghosh M, Merrick DT, Tennis MA, Keith RL. PPARgamma agonism inhibits progression of premalignant lesions in a murine lung squamous cell carcinoma model. Int J Cancer. 2022 Dec 15; 151(12):2195-2205.
Score: 0.394
-
Geraci MW, Keith RL. Con: the case for expanded lung cancer research support. Am J Respir Crit Care Med. 2011 Dec 01; 184(11):1234-6.
Score: 0.187
-
Nemenoff R, Meyer AM, Hudish TM, Mozer AB, Snee A, Narumiya S, Stearman RS, Winn RA, Weiser-Evans M, Geraci MW, Keith RL. Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator--activated receptor gamma. Cancer Prev Res (Phila). 2008 Oct; 1(5):349-56.
Score: 0.150
-
Sompel K, Smith AJ, Hauer C, Elango AP, Clamby ET, Keith RL, Tennis MA. Precision Cut Lung Slices as a Preclinical Model for Non-Small Cell Lung Cancer Chemoprevention. Cancer Prev Res (Phila). 2023 05 01; 16(5):247-258.
Score: 0.103
-
Nakachi I, Rice JL, Coldren CD, Edwards MG, Stearman RS, Glidewell SC, Varella-Garcia M, Franklin WA, Keith RL, Lewis MT, Gao B, Merrick DT, Miller YE, Geraci MW. Application of SNP microarrays to the genome-wide analysis of chromosomal instability in premalignant airway lesions. Cancer Prev Res (Phila). 2014 Feb; 7(2):255-65.
Score: 0.054
-
Tennis MA, Van Scoyk M, Heasley LE, Vandervest K, Weiser-Evans M, Freeman S, Keith RL, Simpson P, Nemenoff RA, Winn RA. Prostacyclin inhibits non-small cell lung cancer growth by a frizzled 9-dependent pathway that is blocked by secreted frizzled-related protein 1. Neoplasia. 2010 Mar; 12(3):244-53.
Score: 0.041
-
Tennis MA, Vanscoyk M, Keith RL, Winn RA. The role of prostacyclin in lung cancer. Transl Res. 2010 Feb; 155(2):57-61.
Score: 0.040
-
Jett JR, Schild SE, Keith RL, Kesler KA. Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007 Sep; 132(3 Suppl):266S-276S.
Score: 0.035
-
Nana-Sinkam P, Golpon H, Keith RL, Oyer RJ, Sotto-Santiago S, Moore MD, Franklin W, Nemenoff RA, Geraci MW. Prostacyclin in human non-small cell lung cancers. Chest. 2004 May; 125(5 Suppl):141S.
Score: 0.028
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|